LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it initiated the commercial launch of the Essenz™ Perfusion System in China, the second-largest market for LivaNova heart-lung machines (HLMs) after the United States. The Essenz Perfusion System, which recently received regulatory approval from China’s National Medical Products Administration (NMPA), enables a patient-tailored perfusion approach rooted in data-driven decision-maki
Related Questions
How will the commercial launch of the Essenz Perfusion System in China impact LivaNova's near‑term revenue and earnings estimates?
What is the competitive landscape for heart‑lung machines in China and how does the Essenz system compare on price, technology, and market share potential?
What timeline and regulatory milestones should we expect for broader adoption and possible reimbursement approvals that could affect the long‑term valuation of LIVN?